Testosterone boosts for treatment of castration resistant prostate cancer: An experimental implementation of intermittent androgen deprivation

Prostate

Volumn 73, Issue 15, 2013, Pages 1699-1709

  Thelen, Paul ^a   Heinrich, Elmar ^a   Bremmer, Felix ^a   Trojan, Lutz ^a   Strauss, Arne ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

Author keywords

androgen receptor; castration resistant prostate cancer (CRPC); intermittent androgen deprivation (IAD); resistance mechanisms; therapy resistance

Indexed keywords

ANDROGEN RECEPTOR; BROXURIDINE; TESTOSTERONE;

ACCLIMATIZATION; ANDROGEN DEPRIVATION THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METASTASIS; CANCER CELL CULTURE; CANCER GROWTH; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE AMPLIFICATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; WESTERN BLOTTING;

ANDROGEN RECEPTOR; CASTRATION RESISTANT PROSTATE CANCER (CRPC); INTERMITTENT ANDROGEN DEPRIVATION (IAD); RESISTANCE MECHANISMS; THERAPY RESISTANCE;

ANDROGENS; ANIMALS; BONE NEOPLASMS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, NUDE; ORCHIECTOMY; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; TESTOSTERONE;

EID: 84884905467     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22711     Document Type: Article

References (49)

1. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P,. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 2007; 18 (3): 581-592.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D,. Global cancer statistics. CA Cancer J Clin 2011; 61 (2): 69-90.
3. Knudsen KE, Penning TM,. Partners in crime: Deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metab 2010; 21 (5): 315-324.
4. Pezaro C, Attard G,. Prostate cancer in 2011: Redefining the therapeutic landscape for CRPC. Nat Rev Urol 2012; 9 (2): 63-64.
5. Sadar MD,. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res 2011; 71 (4): 1208-1213.
6. Waltering KK, Urbanucci A, Visakorpi T,. Androgen receptor (AR) aberrations in castration-resistant prostate cancer. Mol Cell Endocrinol 2012; 360 (1-2): 38-43.
7. Lu-Yao GL, Albertsen PC, Li H, Moore DF, Shih W, Lin Y, DiPaola RS, Yao SL,. Does primary androgen-deprivation therapy delay the receipt of secondary cancer therapy for localized prostate cancer ? Eur Urol 2012; 62 (6): 966-972.
8. Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L,. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med 2012; 367 (10): 895-903.
9. Mitin T, Efstathiou JA, Shipley WU,. Urological cancer. The benefits of intermittent androgen-deprivation therapy. Nat Rev Clin Oncol 2012; 9 (12): 672-673.
10. Salonen AJ, Taari K, Ala-Opas M, Viitanen J, Lundstedt S, Tammela TL,. Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised finnprostate study VII: Quality of life and adverse effects. Eur Urol 2013; 63 (1): 111-120.
11. Abrahamsson PA,. Potential benefits of intermittent androgen suppression therapy in the treatment of prostate cancer: A systematic review of the literature. Eur Urol 2010; 57 (1): 49-59.
12. Buchan NC, Goldenberg SL,. Intermittent versus continuous androgen suppression therapy: Do we have consensus yet ? Curr Oncol 2010; 17 (Suppl 2): S45-S48.
13. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Schmid HP, Van der Kwast T, Wiegel T, Zattoni F, Heidenreich A,. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011; 59 (4): 572-583.
14. Vander Griend DJ, Litvinov IV, Isaacs JT,. Stabilizing androgen receptor in mitosis inhibits prostate cancer proliferation. Cell Cycle 2007; 6 (6): 647-651.
15. Denmeade SR, Isaacs JT,. Bipolar androgen therapy: The rationale for rapid cycling of supraphysiologic androgen/ablation in men with castration resistant prostate cancer. Prostate 2010; 70 (14): 1600-1607.
16. Isaacs JT, D'Antonio JM, Chen S, Antony L, Dalrymple SP, Ndikuyeze GH, Luo J, Denmeade SR,. Adaptive auto-regulation of androgen receptor provides a paradigm shifting rationale for bipolar androgen therapy (BAT) for castrate resistant human prostate cancer. Prostate 2012; 72 (14): 1491-1505.
17. Bruchovsky N, Klotz L, Crook J, Goldenberg SL,. Locally advanced prostate cancer-biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer 2007; 109 (5): 858-867.
18. Mottet N,. Intermittent androgen deprivation therapy in prostate cancer: Is everything so clear ? Eur Urol 2013; 63 (1): 121-122.
19. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25 (4): 402-408.
20. Stettner M, Kaulfuss S, Burfeind P, Schweyer S, Strauss A, Ringert RH, Thelen P,. The relevance of estrogen receptor-beta expression to the antiproliferative effects observed with histone deacetylase inhibitors and phytoestrogens in prostate cancer treatment. Mol Cancer Ther 2007; 6 (10): 2626-2633.
21. Waltering KK, Helenius MA, Sahu B, Manni V, Linja MJ, Janne OA, Visakorpi T,. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009; 69 (20): 8141-8149.
22. Sharma A, Yeow WS, Ertel A, Coleman I, Clegg N, Thangavel C, Morrissey C, Zhang X, Comstock CE, Witkiewicz AK, Gomella L, Knudsen ES, Nelson PS, Knudsen KE,. The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest 2010; 120 (12): 4478-4492.
23. Sedelaar JP, Isaacs JT,. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. Prostate 2009; 69 (16): 1724-1729.
24. Morris MJ, Huang D, Kelly WK, Slovin SF, Stephenson RD, Eicher C, Delacruz A, Curley T, Schwartz LH, Scher HI,. Phase 1 trial of high-dose exogenous testosterone in patients with castration-resistant metastatic prostate cancer. Eur Urol 2009; 56 (2): 237-244.
25. Szmulewitz R, Mohile S, Posadas E, Kunnavakkam R, Karrison T, Manchen E, Stadler WM,. A randomized phase 1 study of testosterone replacement for patients with low-risk castration-resistant prostate cancer. Eur Urol 2009; 56 (1): 97-103.
26. Pearson OH,. Discussion of Dr. Huggins' paper: Control of cancers of man by endocrinological methods. Cancer Res 1957; 17 (5): 473-479.
27. Prout GR Jr, Brewer WR,. Response of men with advanced prostatic carcinoma to exogenous administration of testosterone. Cancer 1967; 20 (11): 1871-1878.
28. Cai C, Wang H, Xu Y, Chen S, Balk SP,. Reactivation of androgen receptor-regulated TMPRSS2: ERG gene expression in castration resistant prostate cancer. Cancer Res 2009; 69 (15): 6027-6032.
29. Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL,. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci USA 2010; 107 (39): 16759-16765.
30. Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J,. Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res 2012; 72 (14): 3457-3462.
31. Cheng J, Wu Y, Mohler JL, Ip C,. The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reduction. Cancer Biol Ther 2010; 9 (12): 1033-1042.
32. Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100 (3): 170-183.
33. Tsihlias J, Zhang W, Bhattacharya N, Flanagan M, Klotz L, Slingerland J,. Involvement of p27Kip1 in G1 arrest by high dose 5 alpha-dihydrotestosterone in LNCaP human prostate cancer cells. Oncogene 2000; 19 (5): 670-679.
34. Jiang J, Pan Y, Regan KM, Wu C, Zhang X, Tindall DJ, Huang H,. Androgens repress expression of the F-box protein Skp2 via p107 dependent and independent mechanisms in LNCaP prostate cancer cells. Prostate 2012; 72 (2): 225-232.
35. Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S,. Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice. Cancer Res 2005; 65 (6): 2082-2084.
36. Joly-Pharaboz MO, Ruffion A, Roch A, Michel-Calemard L, Andre J, Chantepie J, Nicolas B, Panaye G,. Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line. J Ster Biochem Mol Biol 2000; 73 (5): 237-249.
37. Kokontis J, Takakura K, Hay N, Liao S,. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. Cancer Res 1994; 54 (6): 1566-1573.
38. Langeler EG, van Uffelen CJ, Blankenstein MA, van Steenbrugge GJ, Mulder E,. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP. Prostate 1993; 23 (3): 213-223.
39. Sonnenschein C, Olea N, Pasanen ME, Soto AM,. Negative controls of cell proliferation: Human prostate cancer cells and androgens. Cancer Res 1989; 49 (13): 3474-3481.
40. Umekita Y, Hiipakka RA, Kokontis JM, Liao S,. Human prostate tumor growth in athymic mice: Inhibition by androgens and stimulation by finasteride. Proc Natl Acad Sci USA 1996; 93 (21): 11802-11807.
41. Wolf DA, Schulz P, Fittler F,. Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP. Br J cancer 1991; 64 (1): 47-53.
42. Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM,. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase. Endocrinology 2000; 141 (5): 1699-1704.
43. Yuan S, Trachtenberg J, Mills GB, Brown TJ, Xu F, Keating A,. Androgen-induced inhibition of cell proliferation in an androgen-insensitive prostate cancer cell line (PC-3) transfected with a human androgen receptor complementary DNA. Cancer Res 1993; 53 (6): 1304-1311.
44. Isom-Batz G, Bianco FJ Jr, Kattan MW, Mulhall JP, Lilja H, Eastham JA,. Testosterone as a predictor of pathological stage in clinically localized prostate cancer. J Urol 2005; 173 (6): 1935-1937.
45. Morgentaler A, Traish AM,. Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55 (2): 310-320.
46. Rhoden EL, Riedner CE, Morgentaler A,. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 2008; 179 (5): 1741-1744.
47. Teloken C, Da Ros CT, Caraver F, Weber FA, Cavalheiro AP, Graziottin TM,. Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: Hypogonadism represents bad prognosis in prostate cancer. J Urol 2005; 174 (6): 2178-2180.
48. Morgentaler A,. Goodbye androgen hypothesis hello saturation model. Eur Urol 2012; 62 (5): 765-767.
49. Muller RL, Gerber L, Moreira DM, Andriole G, Castro-Santamaria R, Freedland SJ,. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the reduction by dutasteride of prostate cancer events trial. Eur Urol 2012; 62 (5): 757-764.